Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade

被引：0
作者：
Li, Zelin [1 ]
Liu, Shuhan [1 ]
Liu, Deyu [2 ]
Yang, Kangping [3 ]
Xiong, Jing [1 ,4 ]
Fang, Ziling [1 ,5 ]
机构：
[1] Nanchang Univ, Affiliated Hosp 1, Jiangxi Med Coll, Nanchang, Peoples R China
[2] Nanchang Univ, Jiangxi Med Coll, Queen Mary Sch, Dept Clin Med, Nanchang, Peoples R China
[3] Nanchang Univ, Affiliated Hosp 2, Jiangxi Med Coll, Nanchang, Peoples R China
[4] Nanchang Univ, Affiliated Hosp 1, Jiangxi Med Coll, Dept Gen Practice, Nanchang, Peoples R China
[5] Nanchang Univ, Affiliated Hosp 1, Jiangxi Med Coll, Dept Oncol, Nanchang, Peoples R China
来源：
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH | 2025年 / 44卷 / 01期
关键词：
Immune checkpoint blockade; Immune escape; Tertiary lymphoid structures; Immune-related adverse events; Immunotherapy; Cancer; T-CELL INFILTRATION; ACQUIRED-RESISTANCE; B-CELLS; IMMUNOTHERAPY RESPONSE; CTLA-4; BLOCKADE; PLASMA-CELLS; INHIBITORS; SURVIVAL; OUTCOMES; CD8(+);
D O I：
10.1186/s13046-025-03318-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
BackgroundImmune checkpoint blockade (ICB) inhibits tumor immune escape and has significantly advanced tumor therapy. However, ICB benefits only a minority of patients treated and may lead to many immune-related adverse events. Therefore, identifying factors that can predict treatment outcomes, enhance synergy with ICB, and mitigate immune-related adverse events is urgently needed.Main textTertiary lymphoid structures (TLS) are ectopic lymphoid tissues that arise from the tumor periphery. They have been found to be associated with better prognosis and improved clinical outcomes after ICB therapy. TLS may help address the problems associated with ICB. The multiple mechanisms of action between TLS and ICB remain unknown. This paper described potential mechanisms of interaction between the two and explored their potential applications.
引用
收藏
页数：17
相关论文
共 114 条
  • [31] Coelho M.A., Et al., Base editing screens map mutations affecting interferon-gamma signaling in cancer, Cancer Cell, 41, 2, pp. 288-e3036, (2023)
  • [32] Zhan T., Rindtorff N., Boutros M., Wnt signaling in cancer, Oncogene, 36, 11, pp. 1461-1473, (2017)
  • [33] Dobosz P., Et al., Challenges of the Immunotherapy: perspectives and limitations of the Immune checkpoint inhibitor treatment, Int J Mol Sci, 23, 5, (2022)
  • [34] Lauss M., Et al., Molecular patterns of resistance to immune checkpoint blockade in melanoma, Nat Commun, 15, 1, (2024)
  • [35] Naimi A., Et al., Tumor immunotherapies by immune checkpoint inhibitors (ICIs)
  • [36] the pros and cons, Cell Commun Signal, 20, 1, (2022)
  • [37] Kon E., Benhar I., Immune checkpoint inhibitor combinations: current efforts and important aspects for success, Drug Resist Updat, 45, pp. 13-29, (2019)
  • [38] Huang X., Et al., VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy, J Hematol Oncol, 13, 1, (2020)
  • [39] Banta K.L., Et al., Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses, Immunity, 55, 3, pp. 512-e5269, (2022)
  • [40] Morad G., Et al., Hallmarks of response, resistance, and toxicity to immune checkpoint blockade, Cell, 184, 21, pp. 5309-5337, (2021)
12345678910